Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas

J. I Ichiro Sasaki, Kenneth K. Tanabe, Kazuhisa Takahashi, Isamu Okamoto, Hisao Fujimoto, Mitsuhiro Matsumoto, Moritaka Suga, Masayuki Ando, Hideyuki Saya

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

Original languageEnglish
Pages (from-to)525-533
Number of pages9
JournalInternational Journal of Oncology
Volume12
Issue number3
Publication statusPublished - 1998 Mar
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Protein Isoforms
Lung
Small Cell Lung Carcinoma
Reverse Transcriptase Polymerase Chain Reaction
Lung Diseases
Carcinoma
Messenger RNA
Proteins

Keywords

  • Adhesion molecule
  • Alternative splicing
  • CD44
  • Immunohistochemistry
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sasaki, J. I. I., Tanabe, K. K., Takahashi, K., Okamoto, I., Fujimoto, H., Matsumoto, M., ... Saya, H. (1998). Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas. International Journal of Oncology, 12(3), 525-533.

Expression of CD44 splicing isoforms in lung cancers : Dominant expression of CD44v8-10 in non-small cell lung carcinomas. / Sasaki, J. I Ichiro; Tanabe, Kenneth K.; Takahashi, Kazuhisa; Okamoto, Isamu; Fujimoto, Hisao; Matsumoto, Mitsuhiro; Suga, Moritaka; Ando, Masayuki; Saya, Hideyuki.

In: International Journal of Oncology, Vol. 12, No. 3, 03.1998, p. 525-533.

Research output: Contribution to journalArticle

Sasaki, JII, Tanabe, KK, Takahashi, K, Okamoto, I, Fujimoto, H, Matsumoto, M, Suga, M, Ando, M & Saya, H 1998, 'Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas', International Journal of Oncology, vol. 12, no. 3, pp. 525-533.
Sasaki JII, Tanabe KK, Takahashi K, Okamoto I, Fujimoto H, Matsumoto M et al. Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas. International Journal of Oncology. 1998 Mar;12(3):525-533.
Sasaki, J. I Ichiro ; Tanabe, Kenneth K. ; Takahashi, Kazuhisa ; Okamoto, Isamu ; Fujimoto, Hisao ; Matsumoto, Mitsuhiro ; Suga, Moritaka ; Ando, Masayuki ; Saya, Hideyuki. / Expression of CD44 splicing isoforms in lung cancers : Dominant expression of CD44v8-10 in non-small cell lung carcinomas. In: International Journal of Oncology. 1998 ; Vol. 12, No. 3. pp. 525-533.
@article{43cd78d03a6440b2b35e45c113422d30,
title = "Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas",
abstract = "We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.",
keywords = "Adhesion molecule, Alternative splicing, CD44, Immunohistochemistry, Lung cancer",
author = "Sasaki, {J. I Ichiro} and Tanabe, {Kenneth K.} and Kazuhisa Takahashi and Isamu Okamoto and Hisao Fujimoto and Mitsuhiro Matsumoto and Moritaka Suga and Masayuki Ando and Hideyuki Saya",
year = "1998",
month = "3",
language = "English",
volume = "12",
pages = "525--533",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Expression of CD44 splicing isoforms in lung cancers

T2 - Dominant expression of CD44v8-10 in non-small cell lung carcinomas

AU - Sasaki, J. I Ichiro

AU - Tanabe, Kenneth K.

AU - Takahashi, Kazuhisa

AU - Okamoto, Isamu

AU - Fujimoto, Hisao

AU - Matsumoto, Mitsuhiro

AU - Suga, Moritaka

AU - Ando, Masayuki

AU - Saya, Hideyuki

PY - 1998/3

Y1 - 1998/3

N2 - We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

AB - We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

KW - Adhesion molecule

KW - Alternative splicing

KW - CD44

KW - Immunohistochemistry

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0031882175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031882175&partnerID=8YFLogxK

M3 - Article

C2 - 9472088

AN - SCOPUS:0031882175

VL - 12

SP - 525

EP - 533

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -